Articles

Videos

Podcasts

Clinical

Pivotal top-line data demonstrate 20vPnC, if approved likely protects against 20 serotypes in 3-dose series and may offer the broadest serotype coverage of any PCV.

Pfizer Reports Positive Study Results for Pneumococcal Conjugate Vaccine in Infants in the EU

Researchers have identified hydroquinine as a potential treatment against drug-resistant bacteria, which can cause infections with a 70% mortality rate.

Anti-Malaria Drug Hydroquinine May Effectively Treat Drug-Resistant Bacteria

Decision is based on interim analysis of Pfizer’s GBS6 in healthy pregnant woman aged 18 to 40 years, who were vaccinated during their second or early third trimesters.

FDA Grants Breakthrough Therapy Designation to Group B Streptococcus Vaccine Candidate

Meropenem IV is an antibacterial medication indicated for the treatment of complicated stomach and skin structure infections.

Daily Medication Pearl: Meropenem IV

Climatic hazards were implicated for enhancing specific aspects of pathogens, increasing capacity of pathogens to cause more severe illness, and diminishing human capacity to cope with pathogens, such as dengue, hepatitis, pneumonia, malaria, and zika.

Study: Climate Hazards Aggravate More than Half of Human Diseases Caused by Pathogens

Zerbaxa is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor.

Daily Medication Pearl: Ceftolozane and Tazobactam (Zerbaxa)

A potential public health benefit of 13-valent pneumococcal conjugate vaccine is the reduction of acute chest syndrome among children with sickle-cell disease.

PCV13 Vaccination May Reduce Incidence of Acute Chest Syndrome for Children with Sickle-Cell Disease

Moxifloxacin hydrochloride (Avelox) is indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria.

Daily Medication Pearl: Moxifloxacin Hydrochloride (Avelox)

Omadacycline (Nuzyra) is indicated for the treatment of adult patients with infections caused by susceptible microorganisms—community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Daily Medication Pearl: Omadacycline (Nuzyra)

Piperacillin and tazobactam (Zosyn) is indicated for treatment of intra-abdominal infections, skin and skin structure infections, female pelvic infections, community-acquired pneumonia, and nosocomial pneumonia.

Daily Medication Pearl: Piperacillin and Tazobactam (Zosyn)

® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.